Vimal Mehta, CEO and President at BioXcel Therapeutics, Inc. (BTAI), sold 120,000 shares at $19.86 ($2.4M) on 2022-12-15, disclosed to the SEC on 2022-12-19.
Open-market sale of $2.4M BTAI by CEO and President. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.86 | 22,794 | $453K | 19.2% |
| 2 | $19.86 | 22,794 | $453K | 19.2% |
| 3 | $20.19 | 7,206 | $145K | 6.2% |
| 4 | $20.19 | 7,206 | $145K | 6.2% |
| 5 | $19.21 | 20,113 | $386K | 16.4% |
| 6 | $19.21 | 20,113 |
| $386K |
| 16.4% |
| 7 | $19.92 | 9,887 | $197K | 8.3% |
| 8 | $19.92 | 9,887 | $197K | 8.3% |
| Total | $19.69 avg | 120,000 | $2.4M | 100% |
| Filing → |
| BTAI | SELL | 2024-09-17 | $1K | — | Filing → |
| BTAI | SELL | 2024-06-18 | $3K | — | Filing → |
| BTAI | SELL | 2024-04-08 | $14K | — | Filing → |